Posted inBusiness Summit Therapeutics Stock Plummets After US FDA Rejects Lung Cancer Drug Summit Therapeutics experiences a sharp stock decline following the FDA's decision to withhold approval for ivonescimab in lung cancer treatment. Posted by srkanalytics.srk@gmail.com November 16, 2026